Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Ovarian Neoplasms 13Uterine Cervical Neoplasms 9Stomach Neoplasms 9Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Endometrial Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Lung Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Rectal Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Appendiceal Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Recurrence 1Peritoneal Neoplasms 1

Interventions

pembrolizumab 2belinostat 2taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1Fluorouracil 1Etoposide 1Drug Therapy 1Cisplatin 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Irinotecan × Gynecologic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡